Product and licensing revenues increased 47% compared to third quarter of 2013; operating loss improved 45% compared to third quarter of 2013
Total revenues for the third quarter of 2014 increased 14%, to
Discontinued operations primarily includes the after-tax gain recognized
on the company’s sale of its medical shape sensing business in
Total revenues grew 11%, to
The company ended the third quarter of 2014 with
“I am very pleased with the improvements we saw in our operating results
for the third quarter," said
Third Quarter Financial and Business Summary
-
Total revenues grew to
$5.4 million in the third quarter of 2014 compared to$4.7 million in the third quarter of 2013. -
Technology development revenues were
$3.1 million for each of the third quarters of 2014 and 2013. -
Products and licensing revenues were
$2.3 million for the third quarter of 2014, up$0.7 million from$1.6 million for the third quarter of 2013. -
Gross profit for the third quarter of 2014 improved to
$2.1 million , or 39% of total revenues, compared to$1.7 million , or 36% of total revenues, for the third quarter of 2013. -
Selling, general and administrative expenses decreased by 5% to
$2.3 million , or 43% of total revenues, for the third quarter of 2014, from$2.4 million , or 52% of total revenues, for the third quarter of 2013. -
Total operating expense decreased to
$2.8 million , or 52% of total revenues, for the third quarter of 2014, from$3.0 million , or 63% of total revenues, for the third quarter of 2013. -
Adjusted EBITDA improved to
$(0.3) million in the third quarter of 2014 from$(0.7) million in the third quarter of 2013. -
Net loss attributable to common stockholders for the third quarter of
2014 increased to
$0.8 million from$0.6 million for the third quarter of 2013. -
Cash and cash equivalents totaled
$14.4 million at September 30, 2014, as compared to$7.8 million at December 31, 2013 and$14.7 million atJune 30, 2014 .
Nine Months Ended
-
Total revenues increased by 11% to
$15.1 million for the nine months ended September 30, 2014 compared to$13.6 million for the nine months ended September 30, 2013. -
Technology development revenues increased by 5% to
$9.0 million for the nine months ended September 30, 2014 from$8.6 million for the nine months ended September 30, 2013. -
Products and licensing revenues increased by 20% from
$5.1 million for the nine months ended September 30, 2013 to$6.1 million for the nine months ended September 30, 2014. -
Gross profit for the nine months ended September 30, 2014 increased by
21% to
$5.6 million , compared to a gross profit of$4.6 million for the nine months ended September 30, 2013. Gross margin percentages increased to 37% of total revenues for the first nine months of 2014 from 34% of total revenues for the first nine months of 2013. -
Selling, general and administrative expenses decreased to
$7.6 million , representing 50%, of total revenues for the nine months ended September 30, 2014, compared to$8.0 million , or 59% of total revenues, for the nine months ended September 30, 2013. -
Total operating expense decreased to
$9.3 million , or 61% of total revenues, for the nine months ended September 30, 2014, from$9.9 million , or 73% of total revenues, for the nine months ended September 30, 2013. -
Adjusted EBITDA improved to
$(2.3) million for the nine months ended September 30, 2014 from$(3.4) million for the nine months ended September 30, 2013. -
Net income attributable to common stockholders improved to
$6.8 million for the nine months ended September 30, 2014, compared to net income attributable to common stockholders of$1.1 million for the nine months ended September 30, 2013, largely as the result of a net after-tax gain of$9.1 million realized on the sale of the company’s medical shape sensing business in the first quarter of 2014.
Non-GAAP Measures
In evaluating the operating performance of its business, Luna’s management excludes certain charges and credits that are required by generally accepted accounting principles (“GAAP”). These non-GAAP results provide useful information to both management and investors by excluding items that the company believes may not be indicative of its operating performance, because either they are unusual and the company does not expect them to recur in the ordinary course of its business or they are unrelated to the ongoing operation of the business in the ordinary course. These non-GAAP measures should be considered in addition to results and guidance prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. The non-GAAP measures included in this press release have been reconciled to the nearest GAAP measure in the table following the financial statements attached to this press release.
Conference Call Information
As previously announced, Luna will conduct an investor conference call
at
About Luna:
Forward-Looking Statements:
The statements in this release that are not historical facts constitute
“forward-looking statements” made pursuant to the safe harbor provision
of the Private Securities Litigation Reform Act of 1995 that involve
risks and uncertainties. These statements include our expectations
regarding the company’s operating results and future growth of the
company’s fiber optic sensing products. Management cautions the reader
that these forward-looking statements are only predictions and are
subject to a number of both known and unknown risks and uncertainties,
and actual results, performance, and/or achievements of the company may
differ materially from the future results, performance, and/or
achievements expressed or implied by these forward-looking statements as
a result of a number of factors. These factors include, without
limitation, failure of demand for the company’s products and services to
meet expectations, technological challenges and those risks and
uncertainties set forth in the company’s periodic reports and other
filings with the
|
Luna Innovations Incorporated |
||||||||||||||||
|
Consolidated Statements of Operations |
||||||||||||||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Revenues: | ||||||||||||||||
| Technology development revenues | $ | 3,067,022 | $ | 3,130,206 | $ | 8,961,909 | $ | 8,564,743 | ||||||||
| Products and licensing revenues | 2,303,508 | 1,568,646 | 6,108,799 | 5,070,441 | ||||||||||||
| Total revenues | 5,370,530 | 4,698,852 | 15,070,708 | 13,635,184 | ||||||||||||
| Cost of revenues: | ||||||||||||||||
| Technology development costs | 2,379,105 | 2,282,061 | 6,793,061 | 6,676,133 | ||||||||||||
| Products and licensing costs | 908,175 | 739,646 | 2,654,305 | 2,322,776 | ||||||||||||
| Total cost of revenues | 3,287,280 | 3,021,707 | 9,447,366 | 8,998,909 | ||||||||||||
| Gross Profit | 2,083,250 | 1,677,145 | 5,623,342 | 4,636,275 | ||||||||||||
| Operating expense: | ||||||||||||||||
| Selling, general and administrative | 2,329,713 | 2,447,972 | 7,551,512 | 7,986,541 | ||||||||||||
| Research, development and engineering | 473,527 | 531,185 | 1,707,190 | 1,932,966 | ||||||||||||
| Total operating expense | 2,803,240 | 2,979,157 | 9,258,702 | 9,919,507 | ||||||||||||
| Operating loss | (719,990 | ) | (1,302,012 | ) | (3,635,360 | ) | (5,283,232 | ) | ||||||||
| Other income/(expense): | ||||||||||||||||
| Other income, net | — | 78,162 | 111,431 | 271,306 | ||||||||||||
| Interest expense | (21,275 | ) | (42,654 | ) | (80,942 | ) | (150,614 | ) | ||||||||
| Total other (expense)/income | (21,275 | ) | 35,508 | 30,489 | 120,692 | |||||||||||
| Loss from continuing operations, before income taxes | (741,265 | ) | (1,266,504 | ) | (3,604,871 | ) | (5,162,540 | ) | ||||||||
| Income tax benefit | (274,709 | ) | (491,925 | ) | (1,419,882 | ) | (2,033,694 | ) | ||||||||
| Net loss from continuing operations | (466,556 | ) | (774,579 | ) | (2,184,989 | ) | (3,128,846 | ) | ||||||||
| Operating (loss)/income from discontinued operations, net of $0.0 million, $0.3 million, $0.0 million and $0.6 million of related income taxes | (52 | ) | 394,556 | (28,127 | ) | 900,179 | ||||||||||
| (Loss)/gain on sale, net of $0.3 million, $0.2 million, $1.6 million and $1.5 million of related income taxes | (277,562 | ) | (233,889 | ) | 9,093,268 | 3,448,270 | ||||||||||
| (Loss)/income from discontinued operations, net of income taxes | (277,614 | ) | 160,667 | 9,065,141 | 4,348,449 | |||||||||||
| Net (loss)/income | (744,170 | ) | (613,912 | ) | 6,880,152 | 1,219,603 | ||||||||||
| Preferred stock dividend | 26,760 | 26,166 | 83,630 | 76,161 | ||||||||||||
| Net (loss)/income attributable to common stockholders | $ | (770,930 | ) | $ | (640,078 | ) | $ | 6,796,522 | $ | 1,143,442 | ||||||
| Net loss per share from continuing operations: | ||||||||||||||||
| Basic | $ | (0.03 | ) | $ | (0.05 | ) | $ | (0.15 | ) | $ | (0.22 | ) | ||||
| Diluted | $ | (0.03 | ) | $ | (0.05 | ) | $ | (0.15 | ) | $ | (0.22 | ) | ||||
| Net (loss)/income per share from discontinued operations: | ||||||||||||||||
| Basic | $ | (0.02 | ) | $ | 0.01 | $ | 0.61 | $ | 0.30 | |||||||
| Diluted | $ | (0.02 | ) | $ | 0.01 | $ | 0.53 | $ | 0.26 | |||||||
| Net (loss)/income per share attributable to common stockholders: | ||||||||||||||||
| Basic | $ | (0.05 | ) | $ | (0.04 | ) | $ | 0.46 | $ | 0.08 | ||||||
| Diluted | $ | (0.05 | ) | $ | (0.04 | ) | $ | 0.40 | $ | 0.07 | ||||||
| Weighted average common shares and common equivalent shares outstanding: | ||||||||||||||||
| Basic | 15,016,429 | 14,441,707 | 14,821,619 | 14,285,829 | ||||||||||||
| Diluted | 15,016,429 | 16,809,498 | 17,185,369 | 16,593,102 | ||||||||||||
|
Luna Innovations Incorporated |
||||||||
|
Consolidated Balance Sheets |
||||||||
|
September 30, |
December 31, |
|||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 14,430,156 | $ | 7,778,541 | ||||
| Accounts receivable, net | 5,267,953 | 5,408,281 | ||||||
| Inventory, net | 3,400,132 | 3,346,177 | ||||||
| Prepaid expenses | 675,933 | 708,974 | ||||||
| Other current assets | 220,207 | 70,208 | ||||||
| Total current assets | 23,994,381 | 17,312,181 | ||||||
| Property and equipment, net | 1,917,164 | 2,060,709 | ||||||
| Intangible assets, net | 180,718 | 288,475 | ||||||
| Other assets | 1,995 | 42,710 | ||||||
| Total assets | $ | 26,094,258 | $ | 19,704,075 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Liabilities: | ||||||||
| Current Liabilities: | ||||||||
| Current portion of long-term debt obligation | $ | 1,000,000 | $ | 1,500,000 | ||||
| Current portion of capital lease obligation | 69,675 | 66,617 | ||||||
| Accounts payable | 1,508,790 | 1,401,764 | ||||||
| Accrued liabilities | 3,458,456 | 3,546,585 | ||||||
| Deferred credits | 404,487 | 691,424 | ||||||
| Total current liabilities | 6,441,408 | 7,206,390 | ||||||
| Long-term debt obligation | — | 625,000 | ||||||
| Long-term lease obligation | 57,662 | 110,307 | ||||||
| Total liabilities | 6,499,070 | 7,941,697 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, par value $ 0.001, 1,321,514 shares authorized, issued and outstanding at September 30, 2014 and December 31, 2013 | 1,322 | 1,322 | ||||||
| Common stock, par value $ 0.001, 100,000,000 shares authorized, 15,049,698 and 14,527,335 shares issued, 15,026,973 and 14,527,335 shares outstanding at September 30, 2014 and December 31, 2013 | 15,387 | 14,842 | ||||||
| Less treasury stock at cost, 22,725 shares at September 30, 2014 and zero at December 31, 2013 | (32,221 | ) | — | |||||
| Additional paid-in capital | 63,824,535 | 62,756,571 | ||||||
| Accumulated deficit | (44,213,835 | ) | (51,010,357 | ) | ||||
| Total stockholders’ equity | 19,595,188 | 11,762,378 | ||||||
| Total liabilities and stockholders’ equity | $ | 26,094,258 | $ | 19,704,075 | ||||
|
Luna Innovations Incorporated |
||||||||
|
Consolidated Statements of Cash Flows |
||||||||
| Nine months ended September 30, | ||||||||
| 2014 | 2013 | |||||||
| (unaudited) | ||||||||
| Cash flows used in operating activities | ||||||||
| Net income | $ | 6,880,152 | $ | 1,219,603 | ||||
| Adjustments to reconcile net income to net cash used in operating activities | ||||||||
| Depreciation and amortization | 491,066 | 711,375 | ||||||
| Share-based compensation | 738,802 | 896,554 | ||||||
| Gain on sale of discontinued operations, net of income taxes | (9,093,268 | ) | (3,448,270 | ) | ||||
| Bad debt expense | — | 124,810 | ||||||
| Tax benefit from utilization of loss from current year operations | (1,437,958 | ) | (1,448,260 | ) | ||||
| Change in assets and liabilities | ||||||||
| Accounts receivable | 139,950 | 1,880,545 | ||||||
| Inventory | (92,320 | ) | (438,592 | ) | ||||
| Other current assets | (170,857 | ) | 26,931 | |||||
| Other assets | 40,715 | 91,376 | ||||||
| Accounts payable and accrued expenses | (98,920 | ) | (600,471 | ) | ||||
| Deferred credits | (286,937 | ) | (274,746 | ) | ||||
| Net cash used in operating activities | (2,889,575 | ) | (1,259,145 | ) | ||||
| Cash flows provided by investing activities | ||||||||
| Acquisition of property and equipment | (199,532 | ) | (161,519 | ) | ||||
| Intangible property costs | (197,683 | ) | (187,928 | ) | ||||
| Proceeds from sale of discontinued operations, net of fees | 10,927,268 | 4,522,460 | ||||||
| Net cash provided by investing activities | 10,530,053 | 4,173,013 | ||||||
| Cash flows (used in)/provided by financing activities | ||||||||
| Payments on capital lease obligations | (49,587 | ) | (40,993 | ) | ||||
| Payment of debt obligations | (1,125,000 | ) | (1,125,000 | ) | ||||
| Purchase of treasury stock | (32,221 | ) | — | |||||
| Proceeds from the exercise of options and warrants | 217,945 | 96,329 | ||||||
| Net cash used in financing activities | (988,863 | ) | (1,069,664 | ) | ||||
| Net increase in cash or cash equivalents | 6,651,615 | 1,844,204 | ||||||
| Cash and cash equivalents-beginning of period | 7,778,541 | 6,340,461 | ||||||
| Cash and cash equivalents-end of period | $ | 14,430,156 | $ | 8,184,665 | ||||
|
Luna Innovations Incorporated |
||||||||||||||||
|
Reconciliation of Net (Loss)/Income to EBITDA and Adjusted EBITDA |
||||||||||||||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Net (loss)/income | $ | (744,170 | ) | $ | (613,912 | ) | $ | 6,880,152 | $ | 1,219,603 | ||||||
| Less (loss)/income from discontinued operations, net of income taxes | (277,614 | ) | 160,667 | 9,065,141 | 4,348,449 | |||||||||||
| Net loss from continuing operations | (466,556 | ) | (774,579 | ) | (2,184,989 | ) | (3,128,846 | ) | ||||||||
| Interest expense | 21,275 | 42,654 | 80,942 | 150,614 | ||||||||||||
| Tax benefit | (274,709 | ) | (491,925 | ) | (1,419,882 | ) | (2,033,694 | ) | ||||||||
| Depreciation and amortization | 154,502 | 222,131 | 491,066 | 711,375 | ||||||||||||
| EBITDA | (565,488 | ) | (1,001,719 | ) | (3,032,863 | ) | (4,300,551 | ) | ||||||||
| Share-based compensation | 250,209 | 278,468 | 738,802 | 896,554 | ||||||||||||
| Adjusted EBITDA | $ | (315,279 | ) | $ | (723,251 | ) | $ | (2,294,061 | ) | $ | (3,403,997 | ) | ||||
Source:
Luna Innovations Incorporated
Investor Contact:
Dale
Messick, CFO
1-540-769-8400
[email protected]